CCR7 and neoplasm: The mesenchymal phenotype is maintained via TGF-β1 expression in both tumor cells and immune cells in the tumor microenvironment, and is supported by CCR7, which drives lymph node metastasis and a poorer OS among patients strongly expressing CCR7.